Application of LC-NMR for the study of the volatile metabolite of MK-0869, a substance P receptor antagonist

被引:12
作者
Elipe, MVS [1 ]
Huskey, SEW [1 ]
Zhu, B [1 ]
机构
[1] Merck Res Labs, Dept Drug Metab, Rahway, NJ 07065 USA
关键词
LC-NMR; volatile metabolite of MK-0869; MK-0869; microsomes containing recombinant human CYP isozymes; O-dealkylation metabolic pathway;
D O I
10.1016/S0731-7085(01)00715-4
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
LC-NMR was applied to identify the polar volatile metabolite of MK-0869. MK-0869, a morpholine-based compound containing a triazolone ring, is a very potent NK1 receptor antagonist. Currently, it is in development as an anti-emesis agent in chemotherapy treatments. The primary metabolites of MK-0869, M1 and M2, are non-polar and lack the triazolone ring. Incubation of[C-14]M1 with liver microsomes from male rats produced a very polar and volatile metabolite, M3. Analysis was not possible by LC-MS or by conventional NMR because of poor ionization, small molecular weight and volatility, leaving chemical derivatization and LC-NMR as alternative methods. Reduction of M3 with NaBH4 resulted in a derivative that had the same retention time as p-fluorophenylethylene glycol on HPLC. A small aliquot of the solution containing M3 was passed through the LC of the LC-NMR system, which was connected on-line with a radioactivity detector. The simultaneous UV and radioactivity chromatograms thus identified the chromatographic UV peak that was associated with the metabolite. Analysis was carried out by stop-flow on another portion of this fraction. From the chemical derivatization and the analysis by LC-NMR, M3 is shown to be p-fluoro-alpha-hydroxyacetophenone. Further studies using LC-NMR showed that M3 could be generated from both M I and M2 in NADPH-dependant reactions catalyzed by microsomes containing recombinant human CYP2C19, CYP1A2 or CYP3A4. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:1431 / 1440
页数:10
相关论文
共 27 条
[1]   NEUROPHARMACOLOGY OF EMESIS INDUCED BY ANTI-CANCER THERAPY [J].
ANDREWS, PLR ;
RAPEPORT, WG ;
SANGER, GJ .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1988, 9 (09) :334-341
[2]   ANTIEMETIC PROFILE OF A NONPEPTIDE NEUROKININ-NK(1) RECEPTOR ANTAGONIST, CP-99,994, IN FERRETS [J].
BOUNTRA, C ;
BUNCE, K ;
DALE, T ;
GARDNER, C ;
JORDAN, C ;
TWISSELL, D ;
WARD, P .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1993, 249 (01) :R3-R4
[3]  
CARLIN JR, 1997, DRUG METAB DISPOS, V251, P100
[4]  
CHANG MM, 1970, J BIOL CHEM, V245, P4784
[5]  
DEAN B, 2000, DRUG METAB REV S2, V32, P267
[6]  
Dear GJ, 1998, RAPID COMMUN MASS SP, V12, P2023, DOI 10.1002/(SICI)1097-0231(19981230)12:24<2023::AID-RCM431>3.0.CO
[7]  
2-6
[8]  
Ehlhardt WJ, 1998, DRUG METAB DISPOS, V26, P42
[9]   Structural optimization affording 2-(R)-(1-(R)-3,5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist [J].
Hale, JJ ;
Mills, SG ;
MacCoss, M ;
Finke, PE ;
Cascieri, MA ;
Sadowski, S ;
Ber, E ;
Chicchi, GG ;
Kurtz, M ;
Metzger, J ;
Eiermann, G ;
Tsou, NN ;
Tattersall, FD ;
Rupniak, NMJ ;
Williams, AR ;
Rycroft, W ;
Hargreaves, R ;
MacIntyre, DE .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (23) :4607-4614
[10]   2(S)-((3,5-bis(trifluoromethyl)benzyl)oxy)-3(S)-phenyl-4-((3-oxo-1,2,4-triazol-5-yl)methyl)morpholine .1. A potent, orally active, morpholine-based human neurokinin-1 receptor antagonist [J].
Hale, JJ ;
Mills, SG ;
MacCoss, M ;
Shah, SK ;
Qi, HB ;
Mathre, DJ ;
Cascieri, MA ;
Sadowski, S ;
Strader, CD ;
MacIntyre, DE ;
Metzger, JM .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (09) :1760-1762